

---

**From:** Elizabeth Holmes  
**To:** Bill Foege (Independent Contractor)  
**Sent:** 10/7/2014 10:42:51 PM  
**Subject:** Re: RE:

We agree. We think it could also be useful in the infection triage and management. We will plan on including it in the staged deployments.

Elizabeth

On Oct 7, 2014, at 10:31 AM, Bill Foege (Independent Contractor) <[Bill.Foege@](mailto:Bill.Foege@)> wrote:

Sorry. Missed this. If a CBC can be easily done, there are times when it would be useful so I would include it. You avoid the clinician wanting it after seeing the initial results and having to repeat the finger stick. Thanks, Bill

---

**From:** Elizabeth Holmes [<mailto:eholmes@theranos.com>]  
**Sent:** Sunday, October 05, 2014 6:00 PM  
**To:** Bill Foege (Independent Contractor)  
**Subject:**

Wonderful to connect Friday. We have all our assay development teams on deck for bringing up the best combination of tests for an Ebola solution. What are your thoughts on the integration and utility of a CBC with Differential (from the same sample and finger-stick that produces the Ebola Nucleic Acid test results, Ebola antibody results, ISE results, and other Nucleic Acid tests (for other fevers of unknown origin and for the variants of Ebola itself))?

Elizabeth

=====  
**PRIVILEGED AND CONFIDENTIAL COMMUNICATION**  
IMPORTANT – This electronic transmission, and any files transmitted with it are confidential and/or legally privileged information. This information is intended solely for the use of the individual or entity to which they are addressed. Any disclosure, retransmission, reproduction, dissemination or other use of the contents of this information by persons or entities other than the intended recipient is strictly prohibited. If you have received this email in error, please contact us immediately and delete all copies. Please note that any views or opinions presented in this email are solely those of the author and do not necessarily represent those of Theranos, Inc. Finally, before opening or using attachments the recipient should check this email and any attachments for the presence of viruses. Theranos, Inc. accepts no liability for any damage caused by any virus transmitted by this email. Our sole responsibility is limited to resupplying any affected attachments.  
Theranos, Inc., 1601 S. California Avenue, Palo Alto, CA, 94304  
650-838-9292 [www.theranos.com](http://www.theranos.com)  
=====